Edition:
India

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

114.60EUR
6:52pm IST
Change (% chg)

€1.50 (+1.33%)
Prev Close
€113.10
Open
€113.20
Day's High
€114.90
Day's Low
€112.50
Volume
37,431
Avg. Vol
121,840
52-wk High
€155.95
52-wk Low
€98.85

Select another date:

Mon, Feb 25 2019

Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion

PARIS French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion

PARIS French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

UPDATE 2-Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 bln

* Takeover worth up to $1.31 billion (Adds share price reaction and analyst comment)

RPT-Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 bln

PARIS, Feb 25 French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 bln

PARIS, Feb 25 French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

Select another date: